Orphan Drug Development
Although each individual disease is rare, their collective prevalence is estimated at around 6%-8% of the population
Read More
Search Results for: Manohara Halasiddappa
- Cambridge researchers develop robotic nerve devices for neurological conditions
- International phase 3 clinical trial for new melanoma treatment recruits first patients
- Nova’s Xromi approved in UK and EU for vaso-occlusive complications of SCD
- Study reveals vitamin D-altered mouse gut bacteria provides better cancer immunity
- Cambridge researchers use AI to accelerate drug design for Parkinson’s disease
